What inputs go into a defensible budget impact model?

A BIM requires the target population size within the specific payer's enrolled membership, the expected uptake or adoption curve over the model horizon, the acquisition cost of the new technology, and quantified offset costs such as avoided procedures, hospitalizations, or complications, following the framework in the ISPOR Budget Impact Analysis Good Practice Task Force II report. AMCP Format submissions to US health plans require a BIM constructed along these lines as a standard component.

Why do payers frequently reject or heavily discount budget impact models?

The most common reason is overstated offset savings: models that assume aggressive reductions in avoided procedures or hospitalizations without strong supporting real-world evidence are routinely discounted or rejected by payer HEOR reviewers, who apply conservative default assumptions when a submission's evidence for offsets is weak. Building the BIM around conservative, well-sourced offset assumptions is generally more persuasive than maximizing the headline net savings figure.

What is a common scoping mistake companies make when building a BIM?

A frequent error is modeling a national or general population rather than the specific enrolled population of the payer under discussion, since a payer evaluating a formulary or coverage decision cares only about the budget impact to its own membership, not to the broader US population. Each payer engagement typically requires a re-scoped or re-run model reflecting that payer's actual population parameters rather than reusing a single generic national model.

Back to Reimbursement & Market Access

ReimbursementAI / ML in Devices Hospital Buyer & ReimbursementBIM

Budget Impact Model

Financial model that estimates the total cost consequences of adopting a new technology to a payer's budget over a defined horizon.

Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 9, 2026

Definition

A Budget Impact Model (BIM) projects the financial impact to a specific payer (commercial plan, Medicare, integrated health system) of adopting a new technology, typically over 3-5 years, accounting for population size, uptake curve, acquisition cost, offset costs (avoided procedures, hospitalizations, complications), and net budget effect. BIM complements cost-effectiveness analysis but answers a different question: 'Can the payer afford it?' rather than 'Is it good value per QALY?'

What the regulation says

Methodology: ISPOR Budget Impact Analysis Good Practice Task Force II report (2014). AMCP Format requires a BIM as part of US payer submissions.

What this means in practice

Most US payer access decisions are influenced more by BIM than by cost-effectiveness analysis, because US payers typically don't apply a formal QALY threshold. A clean, defensible BIM with conservative offset assumptions is often the deciding artifact.

Examples

A commercial health plan uses a BIM to project the added cost of covering a novel gene therapy for a rare disease, considering the number of eligible patients and potential reductions in long-term hospitalization costs.
An integrated delivery network develops a BIM to understand the financial implications of implementing a new diagnostic test for early cancer detection, factoring in test acquisition costs and potential savings from earlier intervention.
Medicare officials evaluate a BIM submitted by a manufacturer to assess the budget impact of including a new cardiac device in its coverage policy, accounting for patient volume and offsets from reduced rehospitalizations.

Common pitfalls

•Overstating offset savings (avoided procedures), payers discount aggressive assumptions heavily.
•Modeling national populations when the payer cares only about its own enrolled population.

Frequently asked questions

A budget impact model answers whether a specific payer can afford to adopt a new technology, projecting net financial impact over a defined horizon (typically three to five years) based on that payer's own population size, uptake curve, and cost offsets, whereas cost-effectiveness analysis answers whether the technology represents good value per outcome gained, typically expressed as cost per QALY. In the US, where most commercial payers do not apply a formal QALY threshold, the budget impact model is frequently the more decision-relevant artifact.

Grouped by theme

Editor's picks

· Hand-selected related concepts

Reimbursement

Value-Based Care(VBC)

Payment tied to outcomes and total cost of care, not volume of services.

Reimbursement

Health Economics and Outcomes Research(HEOR)

Research discipline that generates economic, clinical, and patient-reported evidence to support payer access, HTA submissions, and value demonstration.

Reimbursement

Incremental Cost-Effectiveness Ratio(ICER)

Cost per additional unit of health outcome (often QALY) versus comparator.

Reimbursement

Quality-Adjusted Life Year(QALY)

Outcome metric combining length and quality of life used in HTA.

Reimbursement & Market Access

· From this learning path

Reimbursement

Health Technology Assessment(HTA)

Systematic evaluation of clinical and economic value of a health technology.

Adjacent lesson

Reimbursement

CPT Codes(CPT)

AMA-maintained codes that describe medical procedures and services.

Reimbursement

Current Procedural Terminology Codes(CPT)

AMA-maintained codes used to report medical procedures and services for billing.

Reimbursement

HCPCS Codes(HCPCS)

CMS-maintained codes for products, supplies, and services not in CPT.

Cited by

Where this term appears across MedTech Terms.

Learning paths (1)

Reimbursement & Market AccessLesson 12 of 14

Ecosystems (2)

Latest in MedTech

Sources

3 sources

Every citation below opens the original document. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.

Tier 3Peer-reviewed and registry evidence· 2Tier 4Trade press and expert commentary· 1

Link health: 3 verified· last checked 2026-06-20

ISPOR·1AMCP·1AMA·1

Inline markers like [1] jump to the matching reference above.

My progress

All terms0 / 513

Reimbursement0 / 37

Saved on this device, and to your account when signed in. View studied terms

Full glossary

Browse all terms A to Z, each with a short definition.

On this term

Category: Reimbursement
Acronym: BIM
Sources: 3
Updated: 5/9/2026

Compare with another term

Learn in 60 seconds

Financial model that estimates the total cost consequences of adopting a new technology to a payer's budget over a defined horizon.

·Most US payer access decisions are influenced more by BIM than by cost-effectiveness analysis, because US payers typically don't apply a formal QALY threshold.
·A clean, defensible BIM with conservative offset assumptions is often the deciding artifact.
·BIM complements cost-effectiveness analysis but answers a different question: 'Can the payer afford it?' rather than 'Is it good value per QALY?'

Remember this

Watch out: Overstating offset savings (avoided procedures), payers discount aggressive assumptions heavily.

Related terms

You may also need

Auto-suggested from Reimbursement and shared keywords.

All Reimbursement terms